Greenland Mines Ltd (NASDAQ:GRML)
| Market Cap | 10.75M-67.7% |
| Revenue (ttm) | 0 |
| Net Income | -21.77M-91.7% |
| EPS | -0.14+46.3% |
| Shares Out | 158.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 753,777 |
| Open | 3.85 |
| Previous Close | 3.91 |
| Day's Range | 3.54 - 3.90 |
| 52-Week Range | 0.16 - 18.08 |
| Beta | 2.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
1 qualifying trade · 1 insider · $136.08K bought in the last 90 days
Greenland Mines Ltd Stock Analysis — InsiderScore
See top-rated InsiderScore stocks ›Greenland Mines Ltd scored higher than 2% of companies evaluated by InsiderBuying, and ranked 87th out of 96 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Greenland Mines Ltd bought $136.1K of stock across 1 purchase in the last 90 days, the largest of them $136.1K.
The average purchase added about 15% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
About GRML
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Insider buys and sells on the price
1 year · open-market trades onlyLatest investor presentation
Ask Barron about GRML
$GRML stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GRML holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GRML's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GRML Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GRML Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Professional fees | $3.95M | 87.57% |
| Exploration and evaluation | $561.03K | 12.43% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GRML patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GRML from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GRML
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $328.75K |
| VXFVanguard Extended Market ETF | $316.59K |
Estimated from each fund’s disclosed top holdings × AUM
GRML Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GRML’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: ranks #87 of 96 scored Biotech stocks · sector average 59.3
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+6.9 since Sep 7Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.